Cidara Therapeutics (CDTX) Enterprise Value: 2017-2025
Historic Enterprise Value for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $2.0 billion.
- Cidara Therapeutics' Enterprise Value rose 3982.59% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 498.98%. This contributed to the annual value of -$6.8 million for FY2024, which is 118.77% down from last year.
- Latest data reveals that Cidara Therapeutics reported Enterprise Value of $2.0 billion as of Q3 2025, which was up 1,648.64% from $114.8 million recorded in Q2 2025.
- In the past 5 years, Cidara Therapeutics' Enterprise Value ranged from a high of $2.0 billion in Q3 2025 and a low of -$109.9 million during Q2 2024.
- Moreover, its 3-year median value for Enterprise Value was $51.3 million (2023), whereas its average is $205.4 million.
- As far as peak fluctuations go, Cidara Therapeutics' Enterprise Value plummeted by 314.24% in 2024, and later surged by 3,982.59% in 2025.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Enterprise Value stood at $22.4 million in 2021, then decreased by 4.36% to $21.4 million in 2022, then skyrocketed by 68.08% to $36.0 million in 2023, then slumped by 118.77% to -$6.8 million in 2024, then skyrocketed by 3,982.59% to $2.0 billion in 2025.
- Its last three reported values are $2.0 billion in Q3 2025, $114.8 million for Q2 2025, and $61.4 million during Q1 2025.